Browsed by
Tag: developer

Developer Hines plans new Lewisville business park

Developer Hines plans new Lewisville business park

Houston-based developer Hines is ramping up its industrial building operations with a project planned in Lewisville.


Load Error

Hines – which has been best known in North Texas for its high-profile office and apartment developments – in the last two years has worked to expand its industrial footprint in the area.

The commercial real estate firm has just filed plans for a four-building industrial park at 810 Round Grove Road near State Highway 121.

The Bison Grove Business Park project would contain almost 900,000 square feet of space and is valued at more than $32.5 million, according to filings with the state.

Construction is set to start early next year. Architecture firm Ware Malcomb designed the project.

The Denton County industrial complex is just the latest warehouse and distribution deal by Hines in the D-FW area.

Hines just leased a more than 1 million-square-foot building located south in southern Dallas to digital retail giant Amazon.

The Southlink Logistics Center is on Cleveland Road south of Interstate 20.

Hines built the project off Bonnie View Road as part of a planned larger industrial park.

In 2018, Hines has purchased an industrial park near DFW International Airport. The DFW East Logistics Center is a three-building property near State Highway 161.

More than 23 million square feet of industrial building space is currently under construction in North Texas, one of the largest such totals in the country.


©2020 The Dallas Morning News

Visit The Dallas Morning News at

Distributed by Tribune Content Agency, LLC.

Continue Reading

Source Article Read the rest

COVID-19 drug developer Atea Pharmaceuticals files for IPO (NASDAQ:GILD)

COVID-19 drug developer Atea Pharmaceuticals files for IPO (NASDAQ:GILD)

Atea Pharmaceuticals has filed for its initial public offering.

It’s a clinical-stage biopharmaceutical company focused on antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections.

“Leveraging our deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, we have built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases,” the company says.

And its lead candidate, AT-527, is a novel antiviral for treating patients infected with SARS-CoV-2, which causes COVID-19.

The offering comes via JPMorgan, Morgan Stanley, Evercore ISI and William Blair.

There’s a placeholder registration for $100M in shares. It’s expecting that its shares will trade on Nasdaq Global Market under the symbol AVIR.

It acknowledges competition from various companies working on the treatment of COVID-19, including Gilead Sciences (NASDAQ:GILD), Fujifilm Pharma, Ridgeback Biotherapeutics/Merck (NYSE:MRK), Regeneron (NASDAQ:REGN), Eli Lilly (NYSE:LLY), and others including Moderna, Inovio, Vir Biotechnology, Biogen, Johnson & Johnson, Pfizer, BioNTech, CanSino Biologics, AbbVie, Sanofi Pasteur, AstraZeneca, and Translate Bio.

Source Article Read the rest